Loading…
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
DeFronzo, Ralph A., Lewin, Andrew, Patel, Sanjay, Liu, Dacheng, Kaste, Renee, Woerle, Hans J., Broedl, Uli C.
Published in Diabetes care (01.03.2015)
Published in Diabetes care (01.03.2015)
Get full text
Journal Article
Loading…
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Scirica, Benjamin M., Braunwald, Eugene, Raz, Itamar, Cavender, Matthew A., Morrow, David A., Jarolim, Petr, Udell, Jacob A., Mosenzon, Ofri, Im, KyungAh, Umez-Eronini, Amarachi A., Pollack, Pia S., Hirshberg, Boaz, Frederich, Robert, Lewis, Basil S., McGuire, Darren K., Davidson, Jaime, Steg, Ph. Gabriel, Bhatt, Deepak L.
Published in Circulation (New York, N.Y.) (28.10.2014)
Published in Circulation (New York, N.Y.) (28.10.2014)
Get full text
Journal Article
Loading…
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study
Singh, Sonal, Chang, Hsien-Yen, Richards, Thomas M, Weiner, Jonathan P, Clark, Jeanne M, Segal, Jodi B
Published in JAMA internal medicine (08.04.2013)
Published in JAMA internal medicine (08.04.2013)
Get more information
Journal Article
Loading…
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
Baggio, Laurie L., Varin, Elodie M., Koehler, Jacqueline A., Cao, Xiemin, Lokhnygina, Yuliya, Stevens, Susanna R., Holman, Rury R., Drucker, Daniel J.
Published in Nature communications (28.07.2020)
Published in Nature communications (28.07.2020)
Get full text
Journal Article
Loading…
Loading…
Do we know the true mechanism of action of the DPP‐4 inhibitors?
Andersen, Emilie S., Deacon, Carolyn F., Holst, Jens J.
Published in Diabetes, obesity & metabolism (01.01.2018)
Published in Diabetes, obesity & metabolism (01.01.2018)
Get full text
Journal Article
Loading…
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase‐4 inhibitor plus low‐dose metformin: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study (MEGMI study)
Takahashi, Akihiro, Nomoto, Hiroshi, Yokoyama, Hiroki, Yokozeki, Kei, Furusawa, Sho, Oe, Yuki, Kameda, Reina, Kawata, Shinichiro, Miyoshi, Arina, Nagai, So, Miya, Aika, Kameda, Hiraku, Nakamura, Akinobu, Atsumi, Tatsuya
Published in Diabetes, obesity & metabolism (01.03.2025)
Published in Diabetes, obesity & metabolism (01.03.2025)
Get full text
Journal Article
Loading…
Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double‐blind, randomized controlled trial
Lee, Yong‐ho, Kim, Doo‐Man, Yu, Jae Myung, Choi, Kyung Mook, Kim, Sin Gon, Park, Kang Seo, Son, Hyun‐Shik, Chung, Choon Hee, Ahn, Kyu Jeung, Lee, Soon Hee, Song, Ki‐Ho, Kwon, Su Kyoung, Park, Hyeong Kyu, Won, Kyu Chang, Jang, Hak Chul
Published in Diabetes, obesity & metabolism (01.05.2023)
Published in Diabetes, obesity & metabolism (01.05.2023)
Get full text
Journal Article
Loading…
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Marx, Nikolaus, Rosenstock, Julio, Kahn, Steven E, Zinman, Bernard, Kastelein, John J, Lachin, John M, Espeland, Mark A, Bluhmki, Erich, Mattheus, Michaela, Ryckaert, Bart, Patel, Sanjay, Johansen, Odd Erik, Woerle, Hans-Juergen
Published in Diabetes & vascular disease research (01.05.2015)
Published in Diabetes & vascular disease research (01.05.2015)
Get full text
Journal Article
Loading…
A model‐informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor
Cui, Cheng, Cao, Fangrui, Kong, Iok Ian, Wu, Qinghe, Li, Fangqiong, Li, Haiyan, Liu, Dongyang
Published in Diabetes, obesity & metabolism (01.02.2024)
Published in Diabetes, obesity & metabolism (01.02.2024)
Get full text
Journal Article
Loading…
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin
Kim, Byungwook, Im, Dha Woon, Won, Heejae, Sunwoo, Jung, Han, Seung Seok, Lee, Hajeong, Kim, Dong Ki, Oh, Kook‐Hwan, Joo, Kwon Wook, Kim, Yon Su, Cho, Joo‐Youn, Lee, SeungHwan, Oh, Jaeseong, Jang, In‐Jin, Kim, Yong Chul
Published in Diabetes, obesity & metabolism (01.06.2023)
Published in Diabetes, obesity & metabolism (01.06.2023)
Get full text
Journal Article
Loading…
Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation
Kridin, Khalaf, Avni, Orly, Damiani, Giovanni, Tzur Bitan, Dana, Onn, Erez, Weinstein, Orly, Cohen, Arnon D.
Published in Archives of Dermatological Research (01.01.2023)
Published in Archives of Dermatological Research (01.01.2023)
Get full text
Journal Article
Loading…
Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
Cho, Y.K., Kang, Y.M., Lee, S.E., Lee, J., Park, J.-Y., Lee, W.J., Kim, Y.-J., Jung, C.H.
Published in Diabetes & metabolism (01.11.2018)
Published in Diabetes & metabolism (01.11.2018)
Get full text
Journal Article
Loading…
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
Lindgren, O, Varpuluoma, O, Tuusa, J, Ilonen, J, Huilaja, L, Kokkonen, N, Tasanen, K
Published in Acta dermato-venereologica (01.05.2019)
Published in Acta dermato-venereologica (01.05.2019)
Get full text
Journal Article
Loading…
Loading…
Loading…
Loading…
Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients
McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q., Kothny, W.
Published in Diabetes, obesity & metabolism (01.11.2015)
Published in Diabetes, obesity & metabolism (01.11.2015)
Get full text
Journal Article
Loading…
Pharmacokinetics and safety of evogliptin in hepatically impaired patients
Hong, Taegon, Jin, Byung Hak, Kim, Choon Ok, Yoo, Byung Won, Kim, Dasohm, Lee, Jung Il, Kim, Beom Kyung, Ahn, Sang Hoon, Kim, Do Young, Park, Jun Yong, Park, Min Soo
Published in British journal of clinical pharmacology (01.07.2021)
Published in British journal of clinical pharmacology (01.07.2021)
Get full text
Journal Article